Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access Life Science Investing
Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring Life Science Investing
New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response Life Science Investing
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results Life Science Investing
Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients Life Science Investing
